Skip to main content

ESTUDIO FUNCIONAL Y ESTRUCTURAL DE LAS MODIFICACIONES POST-TRADUCCIONALES POR LA FAMILIA UBIQUITIN/UBIQUITIN-LIKE.

BFU2012-37116

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

ATPase-dependent control of the Mms21 SUMO ligase during DNA repair

  • Bermúdez López, Marcelino
  • Pociño Merino, Irene
  • Sánchez, Humberto
  • Bueno, Andrés
  • Guasch, Clàudia
  • Almedawar, Seba
  • Brú i Virgili, Sergi
  • Garí Marsol, Eloi
  • Wyman, Claire
  • Reverter Cendrós, David
  • Colomina i Gabarrella, Neus
  • Torres Rosell, Jordi
Modification of proteins by SUMO is essential for the maintenance of genome integrity. During DNA replication, the Mms21-branch of the SUMO pathway counteracts recombination intermediates at damaged replication forks, thus facilitating sister chromatid disjunction. The Mms21 SUMO ligase docks to the arm region of the Smc5 protein in the Smc5/6 complex; together, they cooperate during recombinational DNA repair. Yet how the activity of the SUMO ligase is controlled remains unknown. Here we show that the SUMO ligase and the chromosome disjunction functions of Mms21 depend on its docking to an intact and active Smc5/6 complex, indicating that the Smc5/6-Mms21 complex operates as a large SUMO ligase in vivo. In spite of the physical distance separating the E3 and the nucleotide-binding domains in Smc5/6, Mms21-dependent sumoylation requires binding of ATP to Smc5, a step that is part of the ligase mechanism that assists Ubc9 function. The communication is enabled by the presence of a conserved disruption in the coiled coil domain of Smc5, pointing to potential conformational changes for SUMO ligase activation. In accordance, scanning force microscopy of the Smc5-Mms21 heterodimer shows that the molecule is physically remodeled in an ATP-dependent manner. Our results demonstrate that the ATP-binding activity of the Smc5/6 complex is coordinated with its SUMO ligase, through the coiled coil domain of Smc5 and the physical remodeling of the molecule, to promote sumoylation and chromosome disjunction during DNA repair., Work in JTR's laboratory is supported by grants BFU2012-39656 and BFU2013-50245-EXP from the Spanish Ministry of Economy and Competitivity http://www.idi.mineco.gob.es/. DR is supported by grant BFU2012-37116 from the Spanish Ministry of Economy and Competitivity. HS and CW are supported by NanoNextNL http://www.nanonextnl.nl/, a micro and nanotechnology consortium of the Government of the Netherlands and 130 partners. IPM is a recipient of an FPI fellowship from the Spanish Ministry of Economy and Competitivity (BES-2010-034300). HS is a recipient of a Reintegration Grant http://cordis.europa.eu/fp7/ home_en.html, grant FP7-276898). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

  • Sant'Anna, Ricardo
  • Gallego, Pablo
  • Robinson, Lei Z.
  • Pereira-Henriques, Alda
  • Ferreira, Nelson
  • Pinheiro, Francisca
  • Esperante, Sebastian
  • Pallarés, Irantzu
  • Huertas, Óscar
  • Almeida, Maria Rosário
  • Reixach, Natalia
  • Insa, Raul
  • Velázquez-Campoy, Adrián
  • Reverter, David
  • Reig, Nuria
  • Ventura, Salvador
13 pags, 6 figs, 1 tab. -- Supplementary information is available at the Publisher's web, Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists., This work was funded by the Spanish Ministry of Economy and Competitiveness (BFU2013-44763 to S.V., BFU2012-37116 to D.R., RTC-2014-1931-1 to R.I. and BFU2013-47064-P to A.V.-C.), by SUDOE INTERREG IV B (SOE4/P1/E831 to S.V. and A.V.-C.), by the Spanish Ministry of Science and Innovation (BFU2010-19451 to A.V.-C.), by Diputacion General de Aragon (Protein Targets Group B89 to A. V.-C.) and by the National Institutes of Health (NIA, AG-032285 to N. Reixach). S.V. has been granted an ICREA ACADEMIA award. SOM Biotech was funded by the Spanish Ministry of Health DIN 10-13 grant and the Catalan Competitiveness Agency FINEBT10-2-0037 grant. N. Reig and R.I. were funded by a Torres Quevedo grant by the Spanish Ministry of Economy and Competitiveness. R.S. was supported by CAPES-Science without Borders and S.E. by Consejo Nacional de Promocion Cientifica y Tecnologica (CONICET). We also thank Dr. Debora Foguel for the WT-TTR plasmid used in this study to produce recombinant WT-TTR and Dr Antoni Planas and Dr Ellen Cotrina for technical work. The human cardiac AC16 cell line was developed by Mercy M Davidson at Columbia University46. X-ray experiments were performed at the BL-13 beamline at the ALBA synchrotron in collaboration with the ALBA staff., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ATPase-dependent control of the Mms21 SUMO ligase during DNA repair

  • Bermúdez López, Marcelino
  • Pociño Merino, Irene
  • Sánchez, Humberto
  • Bueno, Andrés
  • Guasch, Clàudia
  • Almedawar, Seba
  • Brú i Virgili, Sergi
  • Garí Marsol, Eloi
  • Wyman, Claire
  • Reverter Cendrós, David
  • Colomina i Gabarrella, Neus
  • Torres Rosell, Jordi
Modification of proteins by SUMO is essential for the maintenance of genome integrity. During DNA replication, the Mms21-branch of the SUMO pathway counteracts recombination intermediates at damaged replication forks, thus facilitating sister chromatid disjunction. The Mms21 SUMO ligase docks to the arm region of the Smc5 protein in the Smc5/6 complex; together, they cooperate during recombinational DNA repair. Yet how the activity of the SUMO ligase is controlled remains unknown. Here we show that the SUMO ligase and the chromosome disjunction functions of Mms21 depend on its docking to an intact and active Smc5/6 complex, indicating that the Smc5/6-Mms21 complex operates as a large SUMO ligase in vivo. In spite of the physical distance separating the E3 and the nucleotide-binding domains in Smc5/6, Mms21-dependent sumoylation requires binding of ATP to Smc5, a step that is part of the ligase mechanism that assists Ubc9 function. The communication is enabled by the presence of a conserved disruption in the coiled coil domain of Smc5, pointing to potential conformational changes for SUMO ligase activation. In accordance, scanning force microscopy of the Smc5-Mms21 heterodimer shows that the molecule is physically remodeled in an ATP-dependent manner. Our results demonstrate that the ATP-binding activity of the Smc5/6 complex is coordinated with its SUMO ligase, through the coiled coil domain of Smc5 and the physical remodeling of the molecule, to promote sumoylation and chromosome disjunction during DNA repair., Work in JTR's laboratory is supported by grants BFU2012-39656 and BFU2013-50245-EXP from the Spanish Ministry of Economy and Competitivity http://www.idi.mineco.gob.es/. DR is supported by grant BFU2012-37116 from the Spanish Ministry of Economy and Competitivity. HS and CW are supported by NanoNextNL http://www.nanonextnl.nl/, a micro and nanotechnology consortium of the Government of the Netherlands and 130 partners. IPM is a recipient of an FPI fellowship from the Spanish Ministry of Economy and Competitivity (BES-2010-034300). HS is a recipient of a Reintegration Grant http://cordis.europa.eu/fp7/ home_en.html, grant FP7-276898). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization

  • Haq, Tamanna
  • Richards, Mark W.
  • Burgess, Selena G.
  • Gallego Alonso, Pablo
  • Yeoh, Sharon
  • O'Regan, Laura
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Roig, Joan
  • Fry, Andrew M.
  • Bayliss, Richard
Mitotic spindle assembly requires the regulated activities of protein kinases such as Nek7 and Nek9. Nek7 is autoinhibited by the protrusion of Tyr97 into the active site and activated by the Nek9 non-catalytic C-terminal domain (CTD). CTD binding apparently releases autoinhibition because mutation of Tyr97 to phenylalanine increases Nek7 activity independently of Nek9. Here we find that self-association of the Nek9-CTD is needed for Nek7 activation. We map the minimal Nek7 binding region of Nek9 to residues 810-828. A crystal structure of Nek7 Y97F bound to Nek9 810-828 reveals a binding site on the C-lobe of the Nek7 kinase domain. Nek7 Y97F crystallizes as a back-to-back dimer between kinase domain N-lobes, in which the specific contacts within the interface are coupled to the conformation of residue 97. Hence, we propose that the Nek9-CTD activates Nek7 through promoting back-to-back dimerization that releases the autoinhibitory tyrosine residue, a mechanism conserved in unrelated kinase families.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

  • Sant'Anna, Ricardo
  • Gallego Alonso, Pablo
  • Robinson, Lei Z.
  • Pereira-Henriques, Alda
  • Ferreira, Nelson
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Esperante, Sebastián|||0000-0002-5778-6871
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Huertas, Oscar
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Reixach, Natàlia
  • Insa, Raul
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Reig, Núria
  • Ventura, Salvador|||0000-0002-9652-6351
Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists.